Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avadel Pharmaceuticals (AVDL) has shared an update.
Avadel Pharmaceuticals has initiated the Phase 3 REVITALYZ trial, administering the first dose of LUMRYZ, an extended-release oral suspension aimed at treating idiopathic hypersomnia. The trial is a rigorous, placebo-controlled study designed to assess the treatment’s efficacy and safety when taken at bedtime. This marks a significant milestone in the company’s efforts to address this sleep disorder.
See more data about AVDL stock on TipRanks’ Stock Analysis page.